Pilocarpine

Generic Name: Pilocarpine

Brand Names: Betoptic Pilo, Isoptocarpine, Minims Pilocarpine Nitrate, Salagen, Vuity

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₆N_₂O_₂

CAS Number: 92-13-7

Unique Ingredient Identifier: 01MI4Q9DI3

Background: Pilocarpine is a cholinergic muscarinic receptor agonist.

Indication: Pilocarpine oral tablets are indicated for the treatment of dry mouth caused by Sjogren's Syndrome or radiotherapy for cancer of the head and neck.

Pilocarpine ophthalmic formulations are used to treat presbyopia in adults, reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, manage acute angle-closure glaucoma, prevent postoperative elevated IOP associated with laser surgery, and induce miosis.

Associated Conditions: Acute angle-closure glaucoma, Dry Mouth, Glaucoma, Closed-Angle, Increased Intra Ocular Pressure (IOP), Narrow-angle glaucoma, Ocular Hypertension, Open Angle Glaucoma (OAG), Presbyopia, Chronic open-angle glaucoma

Clinical Trials

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Phase 2

Completed

Conditions: Kerato Conjunctivitis Sicca
Dry Eye Disease

Interventions: Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1
Drug: Placebo Ophthalmic Topical Cream
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 2
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 3

First Posted Date: 2021-11-15

Last Posted Date: 2023-07-12

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 226

Registration Number: NCT05119920

Locations: 🇺🇸
Glaukos Investigator, Lynchburg, Virginia, United States

Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients

Phase 1

Conditions: Presbyopia

Interventions: Drug: Pilocarpine Hydrochloride
Drug: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
Drug: Brimonidine Tartrate

First Posted Date: 2021-08-11

Last Posted Date: 2021-08-19

Lead Sponsor: Optall Vision

Target Recruit Count: 11

Registration Number: NCT05001243

Locations: 🇲🇽
Optall Vision, Mexico City, Mexico

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: Vehicle
Drug: Pilocarpine HCl

First Posted Date: 2021-07-30

Last Posted Date: 2023-03-21

Lead Sponsor: Allergan

Target Recruit Count: 230

Registration Number: NCT04983589

Locations: 🇺🇸
Martel Eye Medical Group /ID# 231332, Rancho Cordova, California, United States
🇺🇸
North Valley Eye Medical Group, Inc. /ID# 231270, Mission Hills, California, United States
🇺🇸
Global Research Management /ID# 231300, Glendale, California, United States

and more 20 locations

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: AGN-190584
Drug: Vehicle

First Posted Date: 2021-04-08

Last Posted Date: 2024-10-10

Lead Sponsor: AbbVie

Target Recruit Count: 43

Registration Number: NCT04837482

Locations: 🇦🇺
School of Optometry and Vision Science, Queensland University of Technology /ID# 226378, Brisbane, Queensland, Australia

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: Phentolamine Ophthalmic Solution 0.75%
Drug: Pilocarpine
Other: Placebo

First Posted Date: 2020-12-19

Last Posted Date: 2023-09-07

Lead Sponsor: Ocuphire Pharma, Inc.

Target Recruit Count: 150

Registration Number: NCT04675151

Locations: 🇺🇸
Clinical Site 18, Saint Louis, Missouri, United States
🇺🇸
Clinical Site 12, Laguna Hills, California, United States
🇺🇸
Clinical Site 3, Pittsburg, Kansas, United States

and more 14 locations

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: Pilocarpine Ophthalmic
Drug: Placebo

First Posted Date: 2020-12-08

Last Posted Date: 2021-08-09

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 84

Registration Number: NCT04657172

Locations: 🇺🇸
VISION-1 Study Site #54, Fort Collins, Colorado, United States
🇺🇸
VISION-1 Study Site #21, Azusa, California, United States
🇺🇸
VISION-1 Study Site #53, Orlando, Florida, United States

and more 6 locations